Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth

Nature Communications

Volumn 7, Issue , 2016, Pages

  Nakazawa, Michael S ^a   Eisinger Mathason, T S Karin ^a,b   Sadri, Navid ^a,c   Ochocki, Joshua D ^a   Gade, Terence P F ^a   Amin, Ruchi K ^d   Simon, M Celeste ^a,b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; MYC PROTEIN; PROTEIN; PROTEIN EPAS1; UNCLASSIFIED DRUG; VORINOSTAT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

BIOMARKER; CANCER; GENE EXPRESSION; GROWTH RATE; HYPOXIA; INHIBITION; MUSCLE; PROTEIN; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM SIGNALING; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DEDIFFERENTIATED LIPOSARCOMA; DRUG EFFICACY; EPIGENETICS; FIBROSARCOMA; GENE EXPRESSION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN DEPLETION; RNA SEQUENCE; SOFT TISSUE SARCOMA; ANIMAL; CANCER TRANSPLANTATION; DIAGNOSTIC IMAGING; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEK293 CELL LINE; HINDLIMB; HUMAN; HYPOXIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPOSARCOMA; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; SIGNAL TRANSDUCTION; TUMOR CELL LINE; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CALCIUM SIGNALING; CELL LINE, TUMOR; CELL PROLIFERATION; EPIGENESIS, GENETIC; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HINDLIMB; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; LIPOSARCOMA; MULTIPROTEIN COMPLEXES; NEOPLASM TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA; SIGNAL TRANSDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TOR SERINE-THREONINE KINASES;

EID: 84957604974     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10539     Document Type: Article

References (65)

1. Fletcher, C. D. The evolving classification of soft tissue tumours-an update based on the new 2013 WHO classification. Histopathology 64, 2-11 (2014).
2. Siegel, R., Ma, J., Zou, Z., Jemal, A. Cancer Statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
3. Taylor, B. S. et al. Advances in sarcoma genomics and new therapeutic targets. Nat. Rev. Cancer 11, 541-557 (2011).
4. Quesada, J., Amato, R. The molecular biology of soft-tissue sarcomas and current trends in therapy. Sarcoma 2012, 849456 (2012).
5. Linch, M., Miah, A. B., Thway, K., Judson, I. R., Benson, C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat. Rev. Clin. Oncol. 11, 187-202 (2014).
6. Lorigan, P. et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. 25, 3144-3150 (2007).
7. Lehnhardt, M. et al. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities-an analysis of 140 patients. Langenbecks Arch. Surg. 394, 313-320 (2009).
8. King, J. J., Fayssoux, R. S., Lackman, R. D., Ogilvie, C. M. Early outcomes of soft tissue sarcomas presenting with metastases and treated with chemotherapy. Am. J. Clin. Oncol. 32, 308-313 (2009).
9. Matushansky, I. et al. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev. Anticancer Ther. 9, 1135-1144 (2009).
10. Shintani, K. et al. Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch. 449, 673-681 (2006).
11. Nordsmark, M. et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br. J. Cancer 84, 1070-1075 (2001).
12. Rajendran, J. G. et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur. J. Nucl. Med. Mol. Imaging 30, 695-704 (2003).
13. Bertout, J. A., Patel, S. A., Simon, M. C. The impact of O2 availability on human cancer. Nat. Rev. Cancer 8, 967-975 (2008).
14. Majmundar, A. J., Wong, W. J., Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294-309 (2010).
15. Cockman, M. E. et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumour suppressor protein. J. Biol. Chem. 275, 25733-25741 (2000).
16. Keith, B., Johnson, R. S., Simon, M. C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9-22 (2012).
17. Raval, R. R. et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25, 5675-5686 (2005).
18. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B., Simon, M. C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 23, 9361-9374 (2003).
19. Covello, K. L. et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumour growth. Genes Dev. 20, 557-570 (2006).
20. Mazumdar, J. et al. HIF-2alpha deletion promotes Kras-driven lung tumour development. Proc. Natl Acad. Sci. USA 107, 14182-14187 (2010).
21. Sun, H. X. et al. Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/E2F transcription factor 1-dependent apoptotic pathway. Hepatology 57, 1088-1097 (2013).
22. Scheuermann, T. H. et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat. Chem. Biol. 9, 271-276 (2013).
23. Terzuoli, E. et al. Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res. 70, 6837-6848 (2010).
24. Welsh, S. J. et al. Inhibition of the hypoxia-inducible factor pathway by a G-quadruplex binding small molecule. Sci. Rep. 3, 2799 (2013).
25. Eisinger-Mathason, T. S. et al. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 3, 1190-1205 (2013).
26. Mito, J. K. et al. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS ONE 4, e8075 (2009).
27. Kirsch, D. G. et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat. Med. 13, 992-997 (2007).
28. Caputo, A. et al. TMEM16A, a membrane protein associated with calciumdependent chloride channel activity. Science 322, 590-594 (2008).
29. Mayer, C., Grummt, I. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene 25, 6384-6391 (2006).
30. Wan, X., Helman, L. J. The biology behind mTOR inhibition in sarcoma. Oncologist 12, 1007-1018 (2007).
31. Timp, W., Feinberg, A. P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 13, 497-510 (2013).
32. Duvic, M. et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109, 31-39 (2007).
33. Gruber, M. et al. Acute postnatal ablation of Hif-2alpha results in anemia. Proc. Natl Acad. Sci. USA 104, 2301-2306 (2007).
34. Barretina, J. et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 42, 715-721 (2010).
35. Gobble, R. M. et al. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res. 71, 2697-2705 (2011).
36. Dang, C. V. MYC on the path to cancer. Cell 149, 22-35 (2012).
37. Sarbassov, D. D., Guertin, D. A., Ali, S. M., Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
38. Pena-Llopis, S. et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J. 30, 3242-3258 (2011).
39. Hay, N., Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945 (2004).
40. West, R. B. et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumours irrespective of KIT or PDGFRA mutation status. Am. J. Pathol. 165, 107-113 (2004).
41. Carles, A. et al. Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display. Oncogene 25, 1821-1831 (2006).
42. Britschgi, A. et al. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc. Natl Acad. Sci. USA 110, E1026-E1034 (2013).
43. Chen, S. et al. CaMKII is involved in cadmium activation of MAPK and mTOR pathways leading to neuronal cell death. J. Neurochem. 119, 1108-1118 (2011).
44. Ke, Z. et al. hsBAFF promotes proliferation and survival in cultured B lymphocytes via calcium signaling activation of mTOR pathway. Cytokine 62, 310-321 (2013).
45. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
46. Geis, T. et al. HIF-2alpha-dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma. Exp. Cell Res. 331, 46-57 (2015).
47. Lachance, G. et al. DNMT3a epigenetic program regulates the HIF-2alpha oxygen-sensing pathway and the cellular response to hypoxia. Proc. Natl Acad. Sci. USA 111, 7783-7788 (2014).
48. Christman, J. K. 5-Azacytidine and 5-aza-20-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21, 5483-5495 (2002).
49. Avalos, J. L., Bever, K. M., Wolberger, C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(\+) cosubstrate specificity of a Sir2 enzyme. Mol. Cell 17, 855-868 (2005).
50. Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840 (2009).
51. Nielsen, T. O., Poulin, N. M., Ladanyi, M. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discov. 5, 124-134 (2015).
52. Brizel, D. M. et al. Tumour oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56, 941-943 (1996).
53. Francis, P. et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8, 73 (2007).
54. Toschi, A., Lee, E., Gadir, N., Ohh, M., Foster, D. A. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J. Biol. Chem. 283, 34495-34499 (2008).
55. Buchholz, B. et al. Hypoxia-inducible factor-1alpha causes renal cyst expansion through calcium-activated chloride secretion. J. Am. Soc. Nephrol. 25, 465-474 (2014).
56. Fernandez, P. C. et al. Genomic targets of the human c-Myc protein. Genes Dev. 17, 1115-1129 (2003).
57. Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A., Simon, M. C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335-347 (2007).
58. Lopez, G. et al. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumours. Cancer Res. 71, 185-196 (2011).
59. Ito, T. et al. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett. 224, 311-319 (2005).
60. Lubieniecka, J. M. et al. Histone deacetylase inhibitors reverse SS18-SSXmediated polycomb silencing of the tumour suppressor early growth response 1 in synovial sarcoma. Cancer Res. 68, 4303-4310 (2008).
61. Yang, C. et al. Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res. 31, 1115-1123 (2011).
62. West, A. C., Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30-39 (2014).
63. Peng, T. et al. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab. Invest. 91, 392-403 (2011).
64. Li, N. et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl Acad. Sci. USA 105, 4796-4801 (2008).
65. Tomita, S., Sinal, C. J., Yim, S. H., Gonzalez, F. J. Conditional disruption of the aryl hydrocarbon receptor nuclear translocator (Arnt) gene leads to loss of target gene induction by the aryl hydrocarbon receptor and hypoxia-inducible factor 1alpha. Mol. Endocrinol. 14, 1674-1681 (2000).